[Research progress on new drugs for the treatment of chronic hepatitis B virus infection].

Q3 Medicine

中华肝脏病杂志 Pub Date : 2025-05-20 DOI:10.3760/cma.j.cn501113-20240521-00258

Y Y Yu, J Li, W X Wang, P Y Fan, F S Wang

{"title":"[Research progress on new drugs for the treatment of chronic hepatitis B virus infection].","authors":"Y Y Yu, J Li, W X Wang, P Y Fan, F S Wang","doi":"10.3760/cma.j.cn501113-20240521-00258","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatitis B virus (HBV) infection is a major global public health problem. There will be about 257 million chronic HBV-infected patients worldwide, according to the World Health Organization's estimation by 2025. Currently, the main drugs for the treatment of chronic HBV infection are nucleos(t)ide analogues and pegylated interferon (PEG-IFN). However, previous research results show that whether it is nucleos(t)ide analogues and PEG-IFN-α monotherapy or combination therapy, or sequential combination therapy, the rate of hepatitis B surface antigen seroconversion in patients is low, and there is still a high risk of disease progression after a certain course of antiviral treatment. Therefore, to achieve the ambitious target of \"eliminating viral hepatitis by 2030\" set by the World Health Organization and help more hepatitis B patients achieve functional cure, a large number of new drugs have been developed and entered clinical trials. This paper summarizes and reviews the types, safety, and efficacy of new drugs to further promote advancements in the field of treatment of chronic HBV infection.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 5","pages":"493-499"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肝脏病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn501113-20240521-00258","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Hepatitis B virus (HBV) infection is a major global public health problem. There will be about 257 million chronic HBV-infected patients worldwide, according to the World Health Organization's estimation by 2025. Currently, the main drugs for the treatment of chronic HBV infection are nucleos(t)ide analogues and pegylated interferon (PEG-IFN). However, previous research results show that whether it is nucleos(t)ide analogues and PEG-IFN-α monotherapy or combination therapy, or sequential combination therapy, the rate of hepatitis B surface antigen seroconversion in patients is low, and there is still a high risk of disease progression after a certain course of antiviral treatment. Therefore, to achieve the ambitious target of "eliminating viral hepatitis by 2030" set by the World Health Organization and help more hepatitis B patients achieve functional cure, a large number of new drugs have been developed and entered clinical trials. This paper summarizes and reviews the types, safety, and efficacy of new drugs to further promote advancements in the field of treatment of chronic HBV infection.

查看原文本刊更多论文

[治疗慢性乙型肝炎病毒感染新药的研究进展]。

乙型肝炎病毒（HBV）感染是一个重大的全球公共卫生问题。据世界卫生组织估计，到2025年，全球将有大约2.57亿慢性乙肝病毒感染者。目前，治疗慢性HBV感染的主要药物是核苷(t)类似物和聚乙二醇干扰素（PEG-IFN）。然而，以往的研究结果表明，无论是核苷(t)类似物与PEG-IFN-α单药治疗还是联合治疗，还是序贯联合治疗，患者乙型肝炎表面抗原血清转换率较低，抗病毒治疗一定疗程后仍有较高的疾病进展风险。因此，为了实现世界卫生组织制定的“到2030年消灭病毒性肝炎”的宏伟目标，帮助更多的乙型肝炎患者实现功能性治愈，大量新药被开发出来并进入临床试验。本文对近年来新药物的种类、安全性和疗效进行了综述，以期进一步促进慢性HBV感染治疗领域的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊